Experienced in Idiopathic Dilatation of the Pulmonary Artery

Dr. Jean M. Elwing

Pulmonary Medicine | Intensive Care Medicine
University Of Cincinnati Physicians Company LLC
200 Albert Sabin Way, 
Cincinnati, OH 
Accepting New Patients
Offers Telehealth
Experienced in Idiopathic Dilatation of the Pulmonary Artery
University Of Cincinnati Physicians Company LLC
200 Albert Sabin Way, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jean Elwing is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Cincinnati, Ohio. Dr. Elwing is rated as an Experienced provider by MediFind in the treatment of Idiopathic Dilatation of the Pulmonary Artery. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Embolectomy. Dr. Elwing is currently accepting new patients.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in OH
Hospital Affiliations
West Chester Hospital
University Of Cincinnati Medical Center, LLC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
200 Albert Sabin Way, Cincinnati, OH 45267
Other Locations
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
68 Cavalier Blvd, Florence, KY 41042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

62 Total Publications

Pulmonary Alveolar Microlithiasis: A Disorder of Pulmonary Phosphate Homeostasis.
Pulmonary Alveolar Microlithiasis: A Disorder of Pulmonary Phosphate Homeostasis.
Journal: Clinics in chest medicine
Published: October 19, 2025
Similar Doctors
Advanced in Idiopathic Dilatation of the Pulmonary Artery
Dr. David W. Wiltse
Pulmonary Medicine
Advanced in Idiopathic Dilatation of the Pulmonary Artery
Dr. David W. Wiltse
Pulmonary Medicine

Trihealth H LLC

7777 Beechmont Ave, 
Cincinnati, OH 
 (9.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Wiltse is a Pulmonary Medicine provider in Cincinnati, Ohio. Dr. Wiltse is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Dilatation of the Pulmonary Artery. His top areas of expertise are Lung Metastases, Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), and Hypersensitivity Pneumonitis. Dr. Wiltse is currently accepting new patients.

Experienced in Idiopathic Dilatation of the Pulmonary Artery
Dr. Daniel A. Ignatiuk
Pediatric Pulmonology | Pediatrics | Pulmonary Medicine
Experienced in Idiopathic Dilatation of the Pulmonary Artery
Dr. Daniel A. Ignatiuk
Pediatric Pulmonology | Pediatrics | Pulmonary Medicine

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.2 miles away)
513-636-4200
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Ignatiuk is a Pediatric Pulmonologist and a Pediatrics provider in Cincinnati, Ohio. Dr. Ignatiuk has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Idiopathic Dilatation of the Pulmonary Artery. His top areas of expertise are Obstructive Sleep Apnea, Sleepwalking (Somnambulism), Congenital Unilateral Pulmonary Hypoplasia, and Duchenne Muscular Dystrophy. Dr. Ignatiuk is currently accepting new patients.

Experienced in Idiopathic Dilatation of the Pulmonary Artery
Dr. Erik B. Hysinger
Pediatric Pulmonology | Pulmonary Medicine
Experienced in Idiopathic Dilatation of the Pulmonary Artery
Dr. Erik B. Hysinger
Pediatric Pulmonology | Pulmonary Medicine
3333 Burnet Ave, Mlc 2021, 
Cincinnati, OH 
 (0.2 miles away)
513-636-6771
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Erik Hysinger is a Pediatric Pulmonologist and a Pulmonary Medicine provider in Cincinnati, Ohio. Dr. Hysinger is rated as an Elite provider by MediFind in the treatment of Idiopathic Dilatation of the Pulmonary Artery. His top areas of expertise are Tracheobronchomalacia, Bronchopulmonary Dysplasia, Acquired Tracheomalacia, Endoscopy, and Advanced Bronchoscopy. Dr. Hysinger is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elwing's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile